Skip to main content
2024 DC-CSEM Conference Main banner
On-Demand

Clinical Coversations

CC13 - From Awareness to Action: Shining a Light on Presymptomatic Type 1 Diabetes

Friday, November 22, 2024
15:35 - 15:55 AT Time
Location: Clinical Conversations Theater 2

    Speaker(s)

  • BRUCE A. PERKINS, MD MPH FRCP(C) (he/him/his)

    Professor of Medicine and Clinician-Scientist, University of Toronto
    The Sam and Judy Pencer Family Chair in Diabetes and Director of the Diabetes Clinical Research Unit Leadership Sinai Centre for Diabetes, Sinai Health System
    University of Toronto
    Toronto, Ontario, Canada

    Disclosure(s): Abbott Diabetes: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); BMO Bank of Montreal: Grant/Research Support (Ongoing); Dexcom: Advisory Board (Ongoing); Insulet Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Medtronic: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Nephris: Advisory Board (Ongoing); Novo Nordisk Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Sanofi: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Vertex: Advisory Board (Ongoing)

Topic: Type 1 diabetes (T1D) is an autoimmune disease that progresses in three stages. In people with T1D, the immune system mistakenly attacks and destroys healthy insulin producing cells, called beta cells. T1D starts with a genetic predisposition. Everyone who develops T1D has these genes, including people with no family history of T1D. The risk for people in the general population (no T1D family history) is about 1 in 300. For those who have a family member with T1D, the risk is 1 in 20, or 15x greater.
there is a knowledge gap that was identified to educate about presymptomatic stages of T1D, different Autoantibodies and the best way to early detect the risk before symptoms development. additionally, there is evidence on the value of early detection that includes but not limited to risk reduction id Diabetes Ketoacidosis

Learning Objectives: Describe T1D as a chronic autoimmune disease resulting in the destruction
of insulin-producing beta cells, and differentiate its various stages
• Discuss the value of different screening approaches for T1D to identify at-risk
patient, prevent complications such diabetic ketoacidosis (DKA) and provide
support for families
• Explore strategies for delaying the progression of T1D, including emerging
therapies under investigation and approval.

Learning Objectives:

  • Describe T1D as a chronic autoimmune disease resulting in the destruction of insulin-producing beta cells, and differentiate its various stages
  • Discuss the value of different screening approaches for T1D to identify at-risk patient, prevent complications such diabetic ketoacidosis (DKA) and provide
  • Explore strategies for delaying the progression of T1D, including emerging therapies under investigation and approval.